Kweyamba, Prisca A.
Hofer, Lorenz M.
Kibondo, Ummi A.
Mwanga, Rehema Y.
Sayi, Rajabu M.
Matwewe, Fatuma
Austin, James W.
Stutz, Susanne
Moore, Sarah J.
Müller, Pie
Tambwe, Mgeni M.
Article History
Received: 5 July 2023
Accepted: 6 September 2023
First Online: 3 October 2023
Declarations
:
: Written informed consent was obtained from all adult study participants prior to commencement of the study. For children under 18 years their parent or guardian consented and the children assented to participate. All study volunteers were provided with artemisinin lumefantrine treatment within 24 h of malaria diagnosis as per Tanzania Guidelines for Diagnosis and Treatment of Malaria [CitationRef removed], administered by a medical officer. No adverse effects were reported among the volunteers throughout the duration of the study. Study activities were approved by the Institutional Review Board (IHI IHI/IRB/No. 04-2022) and the National Institute for Medical Research Tanzania (NIMR/HQ/R.8a/Vol.IX/4172).
: Consent for publication has been sought from Tanzania National Institute of Medical Research (Ref No. BD.242/437/01/15).
: PAK, LMH, UAK, RYM, RMS, FM, SS and MMT have conducted product evaluation for a number of companies including BASF. SS and JWA are employed by BASF corp and are the manufactures of vector control products. All authors have declared no competing interest.